ARTICLE | Clinical News
IMR-687: Ph I started
December 6, 2016 7:59 PM UTC
Imara began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate oral IMR-687 in about 42 healthy volunteers. Imara has exclusive, worldwide rights to IMR-687 from H. Lundbeck (see BioCe...
BCIQ Target Profiles